Recruiting

AI-Powered Chatbot

Sponsor:

University of Michigan Rogel Cancer Center

Code:

NCT07772596

Conditions

Hematopoietic and Lymphatic System Neoplasm

Malignant Solid Neoplasm

Eligibility Criteria

Sex: All

Age: 18 - 39

Healthy Volunteers: Not accepted

Interventions

Artificial Intelligence-based Intervention

Interview

Survey Administration

Study Details

Brief summary:

This clinical trial studies whether an artificial intelligence (AI)-powered supportive care chatbot is helpful for addressing the supportive care needs of young adult cancer survivors. Young adult cancer survivors often experience ongoing and distressing symptoms following treatment, including extreme tiredness and lack of energy, anxiety, and difficulty sleeping. Young adult cancer survivors report a variety of strategies to self-manage these symptoms; however, there remains a gap in targeted interventions focused on the needs in young adult survivors. The AI-powered supportive care chatbot is designed to provide evidence-based information on supportive care for young adult cancer survivors. Users interact with the chatbot by entering free-text questions or selecting from predefined topics to receive tailored educational responses related to supportive care across the cancer continuum, including treatment effects, symptom management, care transitions, and life after cancer. The AI-powered supportive care chatbot may be an effective way to help address the supportive care needs of young adult cancer survivors.

Conditions

Hematopoietic and Lymphatic System Neoplasm

Malignant Solid Neoplasm

Study ID

NCT07772596

Start date

Sep 15, 2026

Status verified date

Oct, 2026

Completion date

Sep, 2028

Anticipated

Primary completion date

Sep, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 39

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • 18 - 39 years old
  • Able to speak/read English
  • Completed primary cancer treatment (e.g., surgery, radiation, chemotherapy, immunotherapy) at least one month prior to the time of consent. Although, participants will be eligible if they are receiving maintenance treatments
  • Report at least one moderate to severe symptom, side effect, or supportive care concern from cancer or its treatment
  • Able to access Wi-Fi/internet
  • Willing to complete surveys electronically

Exclusion Criteria:

  • Completed cancer treatment more than three years ago

Study Design

Enrollment

30 participants

Anticipated

Intervention Model

Single group

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

experimental: Supportive care (AI-powered supportive care chatbot)

Patients interact with AI-powered supportive care chatbot in a self-directed manner for 4 weeks. Following the initial 4-week use period, patients choose to either continue to use the chatbot for an additional 8 weeks or conclude study participation.

Interventions

Artificial Intelligence-based Intervention

Interact with AI-powered supportive care chatbot

Interview

Ancillary studies

Survey Administration

Ancillary studies

Primary outcome measure

  • Acceptability of AI-powered supportive care chatbot [ Time Frame: At end of intervention, assessed up to 12 weeks ]
  • Demand of AI-powered supportive care chatbot [ Time Frame: Up to 12 months ]
  • Implementation of AI-powered supportive care chatbot [ Time Frame: During intervention use, assessed up to 12 weeks ]
  • Retention [ Time Frame: Up to 12 weeks ]
  • Usability of AI-powered supportive care chatbot [ Time Frame: At end of intervention, assessed up to 12 weeks ]
  • Patient Reported Outcomes Measurement Information System measure [ Time Frame: At baseline, 4 weeks, and/or 12 weeks ]
  • Digital Health Literacy Scale [ Time Frame: At baseline ]
  • Interview themes and subthemes [ Time Frame: At end of intervention, assessed up to 12 weeks ]

Central Contacts and Locations

Central contacts

Robert Knoerl

734-764-8617rjknoerl@med.umich.edu

Locations

University of Michigan Rogel Cancer Center

Recruiting

Ann Arbor, Michigan, United States, 48109

Contacts

Robert Knoerl

734-764-8617rjknoerl@med.umich.edu

Principal Investigator:

Robert Knoerl

More Information

Sponsor

University of Michigan Rogel Cancer Center

Last update posted

Oct 15, 2026

Last verified

Oct, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-16. This information was provided to ClinicalTrials.gov by University of Michigan Rogel Cancer Center on 2026-10-15. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.